CAS NO: | 396091-73-9 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity atsomatostatin receptors(subtypessst1/2/3/4/5,pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity[1][2][3]. | ||||||||
IC50& Target | pKi: 8.2 (sst1), 9.0 (sst2), 9.1 (sst3),<7.0 (sst4), 9.9 (sst5)[1] | ||||||||
体外研究 (In Vitro) | Pasireotide exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively)[1]. | ||||||||
体内研究 (In Vivo) | Pasireotide (160 mg/kg/mouth; s.c. for 4 months) significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis inPdx1-Cre[2].
| ||||||||
Clinical Trial | |||||||||
分子量 | 1047.21 | ||||||||
Formula | C58H66N10O9 | ||||||||
CAS 号 | 396091-73-9 | ||||||||
Sequence | Cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-{D-Trp}-Lys-{Tyr(4-Bzl)}-Phe] | ||||||||
Sequence Shortening | Cyclo[{4-(NH2-C2H4-NH-CO-O-)Pro}-Phg-{D-Trp}-K-{Tyr(4-Bzl)}-F] | ||||||||
中文名称 | 帕瑞肽;帕西瑞肽 | ||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |